Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2180599 | 0.93 | CA1 (0.42) | POLBHTR2AHTR1AALDH1A1THRB | |
| SCHEMBL2179252 | 0.88 | SRC (0.47) | POLBHTR2AHTR1AMAPK1SRC | |
| SCHEMBL2181386 | 0.88 | POLB (0.48) | POLBHTR2AHTR1AMAPK1ALDH1A1 | |
| SCHEMBL2181863 | 0.86 | GAA (0.39) | POLBHTR2AHTR1ASRCCA1 | |
| SCHEMBL2180928 | 0.83 | DCTPP1 (0.39) | POLBHTR2AHTR1AALDH1A1SRC | |
| SCHEMBL2182779 | 0.82 | POLB (0.41) | POLBHTR2AHTR1AMAPK1ALDH1A1 | |
| SCHEMBL2180216 | 0.81 | LMNA (0.44) | POLBMAPK1ALDH1A1SRC | |
| SCHEMBL2180487 | 0.81 | SRC (0.41) | POLBHTR2AHTR1AALDH1A1SRC | |
| SCHEMBL2183064 | 0.80 | ALDH1A1 (0.39) | MAPK1ALDH1A1DPP4TLR7 | |
| SCHEMBL2182226 | 0.80 | USP2 (0.41) | MAPK1DPP4SRCCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | TCF4, TCF7L2, CTNNB1 | POLB 254/4885HTR2A 2864/4885HTR1A 2622/4885 |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | DPYD, TYMP, DHFR | POLB 312/4885HTR2A 3556/4885HTR1A 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.